Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
Top Cited Papers
Open Access
- 23 May 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 379 (9834), 2364-2372
- https://doi.org/10.1016/s0140-6736(12)60738-7
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of ageJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studiesBMJ, 2008
- Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic StrokeStroke, 2003
- ATLANTIS TrialStroke, 2002
- The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)Stroke, 2000
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.Stroke, 1993
- Intravenous Tissue Plasminogen Activator Ameliorates the Outcome of Hyperacute Embolic StrokeCerebrovascular Diseases, 1993
- Thrombolysis in acute ischemic stroke: does it work?Stroke, 1992